HPLC determination of erythrocyte methotrexate polyglutamates after low-dose methotrexate therapy in patients with rheumatoid arthritis

Clinical Chemistry

Volumn 49, Issue 10, 2003, Pages 1632-1641

  Dervieux, Thierry ^a   Lein, Diana Orentas ^a   Marcelletti, John ^a   Pischel, Ken ^b   Smith, Katie ^a   Walsh, Michael ^a   Richerson, Russell ^a  

^a Prometheus Laboratories   (United States)

^b SCRIPPS CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINO 10 METHYLPTEROYLDIGLUTAMIC ACID; 4 AMINO 10 METHYLPTEROYLHEPTAGLUTAMIC ACID; 4 AMINO 10 METHYLPTEROYLHEXAGLUTAMIC ACID; 4 AMINO 10 METHYLPTEROYLPENTAGLUTAMIC ACID; 4 AMINO 10 METHYLPTEROYLTETRAGLUTAMIC ACID; 4 AMINO 10 METHYLPTEROYLTRIGLUTAMIC ACID; ACETONITRILE; AMMONIUM ACETATE; BUFFER; GAMMA GLUTAMYL HYDROLASE; GLUTAMIC ACID DERIVATIVE; MERCAPTOETHANOL; METHOTREXATE; METHOTREXATE DERIVATIVE; PERCHLORIC ACID; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DETERMINATION; ERYTHROCYTE; EXTRACTION; FLUORESCENCE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; PHLEBOTOMY; PHOTOOXIDATION; RHEUMATOID ARTHRITIS; STATISTICAL SIGNIFICANCE; TEMPERATURE; TREATMENT OUTCOME;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CALIBRATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; ERYTHROCYTES; HUMANS; METHOTREXATE; MONITORING, PHYSIOLOGIC; POLYGLUTAMIC ACID; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 0141838977     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/49.10.1632     Document Type: Article

References (35)

1. Weinblatt ME, Coblyn JS, Fox DA, Fraser PA, Holdsworth DE, Glass DN, et al. Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med 1985;312:818-22.
2. Kremer JM, Lee JK. The safety and efficacy of the use of methotrexate in long-term therapy for rheumatoid arthritis. Arthritis Rheum 1986;29:822-31.
3. Weinblatt ME, Kaplan H, Germain BF, Block S, Solomon SD, Merriman RC, et al. Methotrexate in rheumatoid arthritis. A five-year prospective multicenter study. Arthritis Rheum 1994;37:1492-8.
4. Walker AM, Funch D, Dreyer NA, Tolman KG, Kremer JM, Alarcon GS, et al. Determinants of serious liver disease among patients receiving low-dose methotrexate for rheumatoid arthritis. Arthritis Rheum 1993;36:329-35.
5. Bannwarth B, Pehourcq F, Schaeverbeke T, Dehais J. Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis. Clin Pharmacokinet 1996;30:194-210.
6. Chabner BA, Allegra CJ, Curt GA, Clendeninn NJ, Baram J, Koizumi S, et al. Polyglutamation of methotrexate. Is methotrexate a prodrug? J Clin Invest 1985;76:907-12.
7. Dervieux T, Brenner TL, Hon YY, Zhou Y, Hancock ML, Sandlund JT, et al. De novo purine synthesis inhibition and antileukemic effects of mercaptopurine alone or in combination with methotrexate in vivo. Blood 2002;100:1240-7.
8. Morabito L, Montesinos MC, Schreibman DM, Balter L, Thompson LF, Resta R, et al. Methotrexate and sulfasalazine promote adenosine release by a mechanism that requires ecto-5′-nucieoti-dase-mediated conversion of adenine nucleotides. J Clin Invest 1998;101:295-300.
9. Cronstein BN, Naime D, Ostad E. The antiinfiammatory mechanism of methotrexate. Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation. J Clin Invest 1993;92:2675-82.
10. Angelis-Stoforidis P, Vajda FJ, Christophidis N. Methotrexate polyglutamate levels in circulating erythrocytes and polymorphs correlate with clinical efficacy in rheumatoid arthritis. Clin Exp Rheumatol 1999;17:313-20.
11. Kremer JM, Galivan J, Streckfuss A, Kamen B. Methotrexate metabolism analysis in blood and liver of rheumatoid arthritis patients. Association with hepatic folate deficiency and formation of polyglutamates. Arthritis Rheum 1986;29:832-5.
12. Chladek J, Martinkova J, Simkova M, Vaneckova J, Koudelkova V, Nozickova M. Pharmacokinetics of low doses of methotrexate in patients with psoriasis over the early period of treatment. Eur J Clin Pharmacol 1998;53:437-44.
13. Masson E, Relling MV, Synold TW, Liu Q, Schuetz JD, Sandlund JT, et al. Accumulation of methotrexate polyglutamates in lymphoblasts is a determinant of antileukemic effects in vivo. A rationale for high-dose methotrexate. J Clin Invest 1996;97:73-80.
14. Schmiegelow K, Schroder H, Gustafsson G, Kristinsson J, Glomstein A, Salmi T, et al. Risk of relapse in childhood acute lymphoblastic leukemia is related to RBC methotrexate and mercaptopurine metabolites during maintenance chemotherapy. Nordic Society for Pediatric Hematology and Oncology. J Clin Oncol 1995;13:345-51.
15. Schmiegelow K, Bjork O, Glomstein A, Kristinsson J, Makipernaa A, Rosthoj S, et al. Intensification of mercaptopurine/methotrexate maintenance chemotherapy may increase the risk of relapse for some children with acute lymphoblastic leukemia. J Clin Oncol 2003;21:1332-9.
16. Dervieux T, Hancock M, Evans W, Pui CH, Relling MV. Effect of methotrexate polyglutamates on thioguanine nucleotide concentrations during continuation therapy of acute lymphoblastic leukemia with mercaptopurine. Leukemia 2002;16:209-12.
17. Bostrom BC, Erdmann GR, Kamen BA. Systemic methotrexate exposure is greater after intrathecal than after oral administration. J Pediatr Hematol Oncol 2003;25:114-7.
18. Kamen BA, Winick N. Analysis of methotrexate polyglutamate derivatives in vivo. Methods Enzymol 1986;122:339-46.
19. Kamen BA, Takach PL, Vatev R, Caston JD. A rapid, radiochemical-ligand binding assay for methotrexate. Anal Biochem 1976;70:54-63.
20. Schroeder H, Heinsvig EM. Enzymatic assay for methotrexate in erythrocytes. Scand J Clin Lab Invest 1985;45:657-9.
21. Salamoun J, Smrz M, Kiss F, Salamounova A. Column liquid chromatography of methotrexate and its metabolites using a post-column photochemical reactor and fluorescence detection. J Chromatogr 1987;419:213-23.
22. 10-meth-ylpteroic acid in biological fluids by liquid chromatography with fluorimetric detection. J Chromatogr 1986;378:173-81.
23. Rubino FM. Separation methods for methotrexate, its structural analogues and metabolites. J Chromatogr B Biomed Sci Appl 2001;764:217-54.
24. Widemann BC, Balis FM, Adamson PC. Dihydrofolate reductase enzyme inhibition assay for plasma methotrexate determination using a 96-well microplate reader. Clin Chem 1999;45:223-8.
25. Allegra CJ, Boarman D. Interaction of methotrexate polyglutamates and dihydrofolate during leucovorin rescue in a human breast cancer cell line (MCF-7). Cancer Res 1990;50:3574-8.
26. Matherly LH, Fry DW, Goldman ID. Role of methotrexate polyglutamylation and cellular energy metabolism in inhibition of methotrexate binding to dihydrofolate reductase by 5-formyltetrahydrofolate in Ehrlich ascites tumor cells in vitro. Cancer Res 1983;43:2694-9.
27. Pfeiffer CM, Gregory JF. Enzymatic deconjugation of erythrocyte polyglutamyl folates during preparation for folate assay: investigation with reversed-phase liquid chromatography. Clin Chem 1996;42:1847-54.
28. Yao R, Schneider E, Ryan TJ, Galivan J. Human γ-glutamyl hydrolase: cloning and characterization of the enzyme expressed in vitro. Proc Natl Acad Sci U S A 1996;93:10134-8.
29. Rhee MS, Lindau-Shepard B, Chave KJ, Galivan J, Ryan TJ. Characterization of human cellular γ-glutamyl hydrolase. Mol Pharmacol 1998;53:1040-6.
30. Allegra CJ, Drake JC, Jolivet J, Chabner BA. Inhibition of phosphoribosylaminoimidazolecarboxamide transformylase by methotrexate and dihydrofolic acid polyglutamates. Proc Natl Acad Sci U S A 1985;82:4881-5.
31. Schroder H, Fogh K. Methotrexate and its polyglutamate derivatives in erythrocytes during and after weekly low-dose oral methotrexate therapy of children with acute lymphoblastic leukemia. Cancer Chemother Pharmacol 1988;21:145-9.
32. Da Costa M, Iqbal MP. The transport and accumulation of methotrexate in human erythrocytes. Cancer 1981;48:2427-32.
33. Kamen BA, Holcenberg JS, Turo K, Whitehead VM. Methotrexate and folate content of erythrocytes in patients receiving oral vs intramuscular therapy with methotrexate. J Pediatr 1984;104:131-3.
34. Baggott JE, Vaughn WH, Hudson BB. Inhibition of 5-aminoimidazole-4-carboxamide ribotide transformylase, adenosine deaminase and 5′-adenylate deaminase by polyglutamates of methotrexate and oxidized folates and by 5-aminoimidazole-4-carboxamide riboside and ribotide. Biochem J 1986;236:193-200.
35. Montesinos MC, Desai A, Delano D, Chen JF, Fink JS, Jacobson MA, et al. Adenosine A2A or A3 receptors are required for inhibition of inflammation by methotrexate and its analog MX-68. Arthritis Rheum 2003;48:240-7.